SUNSHINE GUOJIAN PHARMACEUTICAL (SHANGHAI) CO., LTD

Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd

688336

CNE1000062X2

Pharmaceuticals

End-of-day quote Shanghai S.E. Other stock markets 2026-03-06			5-day change	1st Jan Change
58.20 ^CNY	+4.64%		-1.99%	-2.30%

Feb. 26	Chinese Drug Regulator Accepts Guojian Pharmaceutical's New Drug Application for Atopic Dermatitis Drug	MT
Feb. 25	Chinese Shares Rise on Tech Boost; Guojian Pharmaceutical Jumps 8%	MT

Sunshine Guojian Pharmaceutical Forecasts Up to 311% Surge in 2025 Profit; Shares Up 8%

Published on 01/27/2026 at 12:25 am EST

MT Newswires

This article is reserved for members

Unlock the article: REGISTER NOW!

100% Free Registration

Already a customer? Log In

Latest news about Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd

Feb. 26	Chinese Drug Regulator Accepts Guojian Pharmaceutical's New Drug Application for Atopic Dermatitis Drug	MT
Feb. 25	Chinese Shares Rise on Tech Boost; Guojian Pharmaceutical Jumps 8%	MT
Feb. 24	Sunshine Guojian Pharmaceutical (Shanghai)'s Attributable Profit Surges 317% in 2025; Shares Up 3%	MT
Feb. 24	Sunshine Guojian Pharmaceutical Shanghai's prelim 2025 net profit up 317.1%	RE
Feb. 24	Sunshine Guojian Pharmaceutical Co., Ltd Reports Earnings Results for the Full Year Ended December 31, 2025	CI
Jan. 27	Sunshine Guojian Pharmaceutical Forecasts Up to 311% Surge in 2025 Profit; Shares Up 8%	MT
Jan. 26	Sunshine Guojian Pharmaceutical Shanghai sees 2025 net profit up about 311.4%	RE
25-10-24	Sunshine Guojian Pharma's Q3 Profit Soars 101%, Revenue Jumps 38%; Shares Dip 7%	MT
25-10-23	Sunshine Guojian Pharmaceutical Co., Ltd Reports Earnings Results for the Nine Months Ended September 30, 2025	CI
25-08-29	Sunshine Guojian Pharmaceutical Co., Ltd Reports Earnings Results for the Half Year Ended June 30, 2025	CI
25-06-23	Sunshine Guojian Pharmaceutical Co., Ltd(SHSE:688336) added to Shanghai Stock Exchange Health Care Sector Index	CI
25-06-05	Sunshine Guojian Pharmaceutical Advances Gout Drug Toward Approval in China	MT
25-05-27	China stocks end lower, dragged by auto and gold miners	RE
25-05-19	Sunshine Guojian Says Co And Affiliates Have Granted Pfizer An Exclusive License On Commercialization Of Cancer Drug	RE
25-04-22	Sunshine Guojian Pharmaceutical Co., Ltd Reports Earnings Results for the First Quarter Ended March 31, 2025	CI

Chart Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd

Duration

Period

Chart Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd

688336: Dynamic Chart

Sunshine Guojian Pharmaceutical Shanghai Co Ltd is a China-based company mainly engaged in the research and development, industrialization and commercialization of antibody drugs. Its products are mainly used to treat major diseases such as autoimmune diseases and tumors. The Companyâ€™s product, recombinant human type II tumor necrosis factor receptor-antibody fusion protein (trade name: YISAIPU), is a fully human antibody drug used to treat rheumatoid arthritis, ankylosing spondylitis and psoriasis. The Company mainly conducts its businesses in Mainland China.

Employees

995

Sector

Pharmaceuticals

Calendar

Mar. 31 - Earnings release - Annual 2025

More about the company